Kelonia Therapeutics – In Vivo CAR-T Clinical Update
Kelonia Therapeutics presented updated ASCO 2026 data supporting continued advancement of its in vivo CAR-T platform, which engineers CAR-T cells directly inside patients using targeted lentiviral delivery technology.
